ReviewJournal of clinical and experimental hepatology
Encephalopathy in Cirrhosis: Prevention and Management.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Changing Etiological Patterns and Predictors of In-Hospital Mortality in Decompensated Cirrhosis: A 10-Year Cohort Study Before and After COVID-19.Diseases (Basel, Switzerland) · 2026Article
- Secondary Prophylaxis of Hepatic encephalopathy in Liver cirrhosis: Rifixamine plus Probiotics vs. Rifixamine alone.Pakistan journal of medical sciences · 2026Article
- Beyond bones: Revisiting the role of vitamin D in chronic liver disease.World journal of hepatology · 2025Review
- Incidental Findings in Clinical Practice: A Case of Hepatic Encephalopathy and Subsequent Lung Cancer Detection.Cureus · 2025Article
- Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data.Frontiers in pharmacology · 2025Article
- The Role of Neuroinflammation in the Pathogenesis of Hepatic Encephalopathy.Journal of immunology research · 2025Review
- The Role of Vitamin D Deficiency in Hepatic Encephalopathy: A Review of Pathophysiology, Clinical Outcomes, and Therapeutic Potential.Nutrients · 2024Review
- Marked Increase in Zinc Concentration of Ascitic Fluid After Cell-free and Concentrated Ascites Reinfusion Therapy in Patients With Cirrhotic Refractory Ascites: A Retrospective Observational Study.In vivo (Athens, Greece)Observational
- Management of Portal Hypertension.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a major neuropsychiatric complication of cirrhosis. The clinical manifestations of HE ranges from mild confusion, disorientation to altered behaviour and coma in advanced stages. HE is an important cause of recurrent admissions in liver cirrhosis patients. HE is the most common cause of altered mentation in a patient of liver cirrhosis. Lactulose and rifaximin are approved treatment options for the treatment of HE. In patients who have localised neurological signs or are not improving with lactulose and rifaximin should be investigated for other causes of altered sensorium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.